Hepatitis Therapeutics Market Review with Forecast Research Report 2018 - 2026

Posted by Aniket Ankushrao on July 19th, 2019

Hepatitis is inflammation of the liver. The condition can progress to form fibrosis or scarring or liver cancer. Hepatitis viruses are the most common cause of hepatitis throughout the globe; however, in certain cases, viral infections, toxic substances such as certain drugs, and autoimmune diseases can also lead to hepatitis. There are five different type of hepatitis infection commonly found, referred to as type A,B,C,D, and E. Hepatitis B and C can lead to chronic infections and are the most prevalent cause of liver cancer or cirrhosis.

Hepatitis A and E are caused due to indigestion of contaminated water and food. Hepatitis B, C, and D are caused due to parenteral contact with infected bodily fluids. Common modes of transmission of hepatitis viruses include contaminated blood transfusion and use of contaminated equipment for medical procedures. Hepatitis B is transmitted through mother to the baby. Hepatitis E virus is transmitted through consumption of contaminated water and food. It is the most common cause of hepatitis in developing economies of the world.

Symptoms of hepatitis infection comprise nausea, loss of appetite, diarrhea, pale bowel movements, dark colored urine, and stomach pain. According to reports published by the Centers for Disease Control and Prevention (CDC), approximately 4.4 million people are affected with chronic hepatitis B and C in the U.S. Diagnosis of hepatitis is carried out through liver function tests, ultrasounds, blood tests, and liver biopsy. Liver biopsy is an invasive procedure carried out to determine the effect of infection on the liver. Treatment of hepatitis is executed through administration of therapeutics, such as, antiviral agents, vaccines, and liver transplant.

Major drivers expected to boost the growth of the global hepatitis therapeutics market are increasing patient population, rapidly growing bio-pharmaceutical industry, rising demand for novel therapeutics for effective treatment, increasing awareness, and growing number of public private partnerships. Key restraints of the market, on the other hand, comprise lack of awareness regarding treatment options for this condition in developing economies, lower penetration of therapeutics in the smaller economies in the world, and lack of reimbursement facility in certain regions.

The global hepatitis therapeutics market can be segmented based on disease indication, drug type, distribution channel, and geography. The disease indication segment of the global hepatitis therapeutics market can be divided into Hepatitis A, B, C, D, and E. The drug type segment of the market can be classified into vaccines and anti-viral drugs. In terms of distribution channel, the global hepatitis therapeutics market can be categorized into hospital pharmacies, retail pharmacies, and e-commerce.

The global hepatitis therapeutics market, by geography, can be divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is anticipated to dominate the global hepatitis therapeutics market during the forecast period with the leading market share, followed by Europe. Dominance of North America and Europe in the global hepatitis therapeutics market can be attributed to increase in mergers & acquisitions, rise in demand for hepatitis therapeutics, and presence of well-established health care sector in these regions. Asia Pacific is expected to offer lucrative opportunities to market players in the hepatitis therapeutics market during the forecast period, owing to increasing penetration of global manufacturers in the region, growing population, new product launches, and rising government initiatives to promote diseases awareness. The hepatitis therapeutics market in Latin America and Middle East & Africa is projected to grow significantly during the forecast period on account of expanding health care industry, increasing research & development activities, and introduction of favorable reforms to attract manufacturers to establish their business in these regions.

Request Brochure of the Report:

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=52665

Major players operating in the global hepatitis therapeutics market include F. Hoffmann- La Roche, Merck & Co., Novartis AG, Johnson & Johnson, Bristol-Myers Squibb, and GlaxoSmithKline plc